These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 25818758)

  • 21. Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis.
    Schurgers LJ; Spronk HM
    Thromb Haemost; 2014 Nov; 112(5):909-17. PubMed ID: 25298033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome.
    Seiffge DJ; Hooff RJ; Nolte CH; Béjot Y; Turc G; Ikenberg B; Berge E; Persike M; Dequatre-Ponchelle N; Strbian D; Pfeilschifter W; Zini A; Tveiten A; Næss H; Michel P; Sztajzel R; Luft A; Gensicke H; Traenka C; Hert L; Scheitz JF; De Marchis GM; Bonati LH; Peters N; Charidimou A; Werring DJ; Palm F; Reinhard M; Niesen WD; Nagao T; Pezzini A; Caso V; Nederkoorn PJ; Kägi G; von Hessling A; Padjen V; Cordonnier C; Erdur H; Lyrer PA; Brouns R; Steiner T; Tatlisumak T; Engelter ST;
    Circulation; 2015 Sep; 132(13):1261-9. PubMed ID: 26232277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI).
    Gibson CM; Mehran R; Bode C; Halperin J; Verheugt F; Wildgoose P; van Eickels M; Lip GY; Cohen M; Husted S; Peterson E; Fox K
    Am Heart J; 2015 Apr; 169(4):472-8.e5. PubMed ID: 25819853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New anticoagulants for atrial fibrillation.
    De Caterina R; Kristensen SD; Renda G
    J Cardiovasc Med (Hagerstown); 2009 Jun; 10(6):446-53. PubMed ID: 19365276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rivaroxaban in atrial fibrillation cardioversion: insights from the X-VeRT trial.
    Farag M; Gorog DA
    Future Cardiol; 2015 Mar; 11(2):147-51. PubMed ID: 25760874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Old and new anticoagulant agents for the prevention and treatment of patients with ischemic stroke.
    Martí-Fàbregas J; Mateo J
    Cerebrovasc Dis; 2009; 27 Suppl 1():111-9. PubMed ID: 19342840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
    Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
    Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome.
    Ann Intern Med; 2019 Nov; 171(10):. PubMed ID: 31610579
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
    Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
    Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stroke prevention in atrial fibrillation: impact of novel oral anticoagulants.
    Haft JI
    Clin Appl Thromb Hemost; 2013 Jun; 19(3):241-8. PubMed ID: 22952215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical significance of non-vitamin K antagonist oral anticoagulants in the management of atrial fibrillation.
    Santarpia G; Curcio A; Sibilio G; Indolfi C
    Circ J; 2015; 79(5):914-23. PubMed ID: 25833178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice.
    Łukasik M; Zawilska K; Undas A
    Neurol Neurochir Pol; 2015; 49(3):171-9. PubMed ID: 26048605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Anticoagulation and atrial fibrillation].
    Simmers TA
    Tijdschr Gerontol Geriatr; 2012 Dec; 43(6):308-12. PubMed ID: 23371873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Probable interaction between an oral vitamin K antagonist and turmeric (Curcuma longa).
    Daveluy A; Géniaux H; Thibaud L; Mallaret M; Miremont-Salamé G; Haramburu F
    Therapie; 2014; 69(6):519-20. PubMed ID: 25230280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Frequency of use of oral vitamin K antagonists in patients with atrial fibrillation and cognitive function disturbances].
    Gorzelak P; Zyzak S; Krewko Ł; Mozdzan M; Broncel M
    Pol Merkur Lekarski; 2014 May; 36(215):302-6. PubMed ID: 24964505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral anticoagulant therapy and thrombosis. A case of failure of therapy with vitamin K antagonists.
    Romano P; Messina F; Crosca S
    Int J Cardiol; 2016 Jan; 203():1158-9. PubMed ID: 26608008
    [No Abstract]   [Full Text] [Related]  

  • 37. [Severe overdose in vitamin K antagonist secondary to grapefruit juice absorption].
    Desmard M; Hellmann R; Plantefève G; Mentec H
    Ann Fr Anesth Reanim; 2009 Oct; 28(10):897-9. PubMed ID: 19766437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Summaries for patients. Rivaroxaban in patients transitioned from vitamin K antagonist therapy.
    Ann Intern Med; 2013 Jun; 158(12):I-28. PubMed ID: 23778921
    [No Abstract]   [Full Text] [Related]  

  • 39. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
    ROCKET AF Study Investigators
    Am Heart J; 2010 Mar; 159(3):340-347.e1. PubMed ID: 20211293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Oral anticoagulants. Large study finds minor risk of hemorrhage in the elderly].
    MMW Fortschr Med; 2011 Sep; 153(37):16. PubMed ID: 21950182
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.